JNJ240726P149000
- 0.03
- -0.07-70.00%
Johnson & Johnson Newsroom
AbbVie Raises Outlook as New Immunology Drugs Offset Humira Impact
Newly-Listed Psoriasis Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Bio-Thera Biosimilar to J&J's Stelara Under FDA Review
Check Out What Whales Are Doing With JNJ
Johnson & Johnson (JNJ) Is Attracting Investor Attention: Here Is What You Should Know
Health Care Stocks Steady With Broader Market -- Health Care Roundup
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
Maintain for one month! Johnson & Johnson (JNJ.US) submits new indications for anti-depressant nasal sprays.
On July 22, Johnson & Johnson (JNJ.US) announced the submission of a supplemental New Drug Application (sNDA) to the US FDA.
Time for Healthcare ETFs?
Daiwa Downgrades Johnson & Johnson to Neutral From Outperform, Adjusts Price Target to $150 From $160
Alvotech Launches First Biosimilar of J&J's Stelara in Europe
Sector Update: Health Care Stocks Rise in Monday's Premarket Hours
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
Johnson & Johnson Seeks FDA OK of Spravato as Monotherapy
Express News | Johnson & Johnson Submits Supplemental New Drug Application To FDA Seeking Approval Of SPRAVATO CIII Nasal Spray In Treatment-Resistant Depression
Express News | Johnson & Johnson Seeks U.S. FDA Approval of Spravato® (Esketamine) as the First and Only Monotherapy for Adults With Treatment-Resistant Depression
Guggenheim Adjusts Johnson & Johnson's Price Target to $156 From $160, Maintains Neutral Rating
Express News | J&J : Guggenheim Cuts Target Price to $156 From $160
Buy Rating Affirmed for Johnson & Johnson on Strong Growth and Strategic Acquisitions